Genetic testing for personalized treatment of lung cancer was associated with improved survival, likely due to getting targeted kinase inhibitors to the right patients, a study showed.
Patients whose tumors were genotyped had 28% better overall survival odds than those who couldn’t get a genetic diagnosis for reasons like limited tissue availability (P=0.002), Roman K. Thomas, MD, of the University of Cologne in Germany, and colleagues found.
For the 75% who could be genotyped, treatment recommendations for genetically-tailored cancer therapy with approved drugs or in clinical trials were given.
The genotyped patients had a median overall survival of 31.6 months compared with 15.1 among those not able to be genotyped, for a multivariate-adjusted hazard ratio of 0.719 (95% confidence interval 0.588-0.879).
Read the full, original story here: Genotyping Lung Cancer Linked to Better Survival